The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis.
Yoneda
Misaho
M
Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland.
Brosnan
Jeanette F
JF
Norris
Lucy A
LA
Bonnar
John
J
D000328:Adult; D001777:Blood Coagulation; D015951:Factor Xa / Q000032:analysis; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000096:biosynthesis; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D015233:Models, Statistical; D011247:Pregnancy; D011264:Pregnancy Trimesters; D012306:Risk; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000517:prevention & control*; D013997:Time Factors; D000078222:Tinzaparin
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C036309:fibrin fragment D; D000078222:Tinzaparin; D015951:Factor Xa